

PARTICULARS TO APPEAR ON THE OUTER PACKAGE {CARDBOARD BOX}

1. NAME OF THE VETERINARY MEDICINAL PRODUCT

Nobilis Rhino CV lyophilisate for oculonasal suspension

2. STATEMENT OF ACTIVE SUBSTANCES

Avian metapneumovirus, strain 11/94, Live: $10^{1.5}$ - $10^{3.7}$ TCID₅₀*/dose.

3. PACKAGE SIZE

250 doses
500 doses
1.000 doses
2.500 doses
5.000 doses
10.000 doses
25.000 doses
2 x 250 doses
2 x 500 doses
2 x 1.000 doses
2 x 2.500 doses
2 x 5.000 doses
2 x 10.000 doses
2 x 25.000 doses
5 x 250 doses
5 x 500 doses
5 x 1.000 doses
5 x 2.500 doses
5 x 5.000 doses
5 x 10.000 doses
5 x 25.000 doses
10 x 250 doses
10 x 500 doses
10 x 1.000 doses
10 x 2.500 doses
10 x 5.000 doses
10 x 10.000 doses
10 x 25.000 doses
20 x 250 doses
20 x 500 doses
20 x 1.000 doses
20 x 2.500 doses
20 x 5.000 doses
20 x 10.000 doses
20 x 25.000 doses
50 x 250 doses
50 x 500 doses

50 x 1.000 doses
50 x 2.500 doses
50 x 5.000 doses
50 x 10.000 doses
50 x 25.000 doses

4. TARGET SPECIES

Chicken.

5. INDICATIONS

6. ROUTES OF ADMINISTRATION

Oculonasal or spray use.

7. WITHDRAWAL PERIODS

Withdrawal period: zero days.

8. EXPIRY DATE

Exp. {mm/yyyy}

Once broached use within 2 hours.

9. SPECIAL STORAGE PRECAUTIONS

Store in a refrigerator.

Do not freeze.

Keep the vial in the outer carton in order to protect from light.

10. THE WORDS “READ THE PACKAGE LEAFLET BEFORE USE”

Read the package leaflet before use.

11. THE WORDS “FOR ANIMAL TREATMENT ONLY”

For animal treatment only.

12. THE WORDS “KEEP OUT OF THE SIGHT AND REACH OF CHILDREN”

Keep out of the sight and reach of children.

13. NAME OF THE MARKETING AUTHORISATION HOLDER

Intervet International B.V.

14. MARKETING AUTHORISATION NUMBER

Vm 06376/5061

Vm 06376/3061

15. BATCH NUMBER

Lot {number}

**MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING
UNITS {GLASS VIALS}**

1. NAME OF THE VETERINARY MEDICINAL PRODUCT

Nobilis Rhino CV



2. QUANTITATIVE PARTICULARS OF THE ACTIVE SUBSTANCES

Avian metapneumovirus, Live: $10^{1.5}$ - $10^{3.7}$ TCID₅₀/dose

250 doses
500 doses
1.000 doses
2.500 doses
5.000 doses
10.000 doses
25.000 doses

3. BATCH NUMBER

Lot {number}

4. EXPIRY DATE

Exp. {mm/yyyy}

Once broached use within 2 hours.

PACKAGE LEAFLET

1. Name of the veterinary medicinal product

Nobilis Rhino CV lyophilisate for oculonasal suspension for chickens.

2. Composition

Each dose of reconstituted vaccine contains:

Active substance:

Avian metapneumovirus, strain 11/94, Live: $10^{1.5} - 10^{3.7}$ TCID₅₀ *.

*Tissue culture infective dose 50%

Lyophilisate: white/off-white cake.

3. Target species

Chicken.

4. Indications for use

For broilers, future layers and breeders from one day of age.

Broilers, future layers and breeders

Active immunisation in order to reduce the frequency and the severity of clinical signs due to infection with avian rhinotracheitis virus (avian metapneumovirus).

Onset of immunity: 3 weeks.

Duration of immunity: 16 weeks post-vaccination.

Future layers and breeders

Priming with Nobilis Rhino CV, followed by a second vaccination with an inactivated vaccine containing the avian rhinotracheitis virus strain But1#8544 before the onset of lay results in a reduction of the clinical signs including egg drop, caused by infection with avian rhinotracheitis virus. Protective immunity is maintained for the normal laying period.

5. Contraindications

None.

6. Special warnings

Special warnings:

Vaccinate healthy animals only.

Special precautions for use in the target species:

In order to reduce the circulation of the vaccine strain, all susceptible animals on the site have to be vaccinated properly and preferably at the same time. The vaccine virus can spread to other susceptible species with which they have direct contact. It was shown that the spreading has negligible impact on turkeys, which together with chickens constitute the species that are most susceptible to avian rhinotracheitis virus.

Laying birds:

Do not use in birds in lay and breeding birds and within 4 weeks before the start of the laying period.

Interaction with other medicinal products and other forms of interaction:

Safety and efficacy data are available which demonstrate that this vaccine can be administered on the same day but not mixed with vaccines against infectious bronchitis containing strain H120 and against Newcastle disease containing strains Clone 30 or C2 and infectious bronchitis vaccine (strain IB Ma5) when given on day 1 (the efficacy of the IB Ma5 vaccine has not been investigated).

The company's live vaccine against Gumboro disease (infectious bursal disease) containing the D78 strain can be given 7 days after Nobilis Rhino CV.

No information is available on the safety and efficacy of this vaccine when used with any other veterinary medicinal product except the products mentioned above.

A decision to use this vaccine before or after any other veterinary product therefore needs to be made on a case-by-case basis.

Overdose:

Administration of tenfold the maximum dose by the recommended routes has not resulted in any other effect on the target species than those described above.

Major incompatibilities:

Do not mix with any other veterinary medicinal product.

7. Adverse events

Chicken:

Common (1 to 10 animals / 100 animals treated):	Nasal discharge ¹ , Cough ¹
--	---

¹ Mild. Between 2 to 7 days after administration for 1 to 2 days.

Reporting adverse events is important. It allows continuous safety monitoring of a product. If you notice any side effects, even those not already listed in this package leaflet, or you think that the medicine has not worked, please contact, in the first instance, your veterinarian. You can also report any adverse events to the marketing authorisation holder or the local representative of the marketing authorisation holder using the contact details at the end of this leaflet, or via your national reporting system:

Website: <https://www.gov.uk/report-veterinary-medicine-problem/animal-reacts-medicine>
e-mail: adverse.events@vmd.gov.uk

8. Dosage for each species, routes and method of administration

Oculonasal use via eye- or nose-drop method or via coarse spray, one dose per bird from 1 day old.

9. Advice on correct administration

Oculonasal route

Reconstitute the freeze-dried vaccine in clean, disinfectant- and antiseptic free water to which 2 % liquid skimmed milk is added and administer by means of a standardised dropper. The amount of fluid required for eye- or nose-drop administration depends on the number of doses and the droplet size, but approximately 35 ml per 1,000 doses is used. Apply one drop in a nare or eye. Check that the drop is entirely absorbed before releasing the bird.

After reconstitution the suspension looks homogeneous opalescent to slightly white.

Spray vaccination

The vaccine must be reconstituted with clean, disinfectant- and antiseptic free water to which 2 % of liquid skimmed milk is added. The appropriate number of vials must be opened under water. The volume of vaccine suspension must be sufficient to ensure a homogeneous vaccination of the birds.

Depending on the age of the chickens to be vaccinated and the rearing system, take 250 to 500 ml of water per 1,000 doses. The vaccine suspension is to be sprayed evenly over the appropriate number of animals at a distance of 30 - 40 cm with a regular spraying apparatus, preferably when the animals sit together under a dim light. The spray apparatus must be free from sediments, corrosion and traces of disinfectants and ideally should be used for vaccination purposes only.

If applicable, reduce ventilation to prevent loss of spray.

After reconstitution the suspension looks clear.

10. Withdrawal periods

Zero days.

11. Special storage precautions

Keep out of the sight and reach of children.

Store in a refrigerator (2 °C to 8 °C).

Do not freeze.

Keep the vial in the outer carton in order to protect from light.

Do not use this veterinary medicinal product after the expiry date which is stated on the label. The expiry date refers to the last day of that month.

Shelf-life after reconstitution according to directions: 2 hours.

12. Special precautions for disposal

Medicines should not be disposed of via wastewater or household waste.

Dispose of waste material by boiling, incineration or immersion in an appropriate disinfectant in accordance with national requirements.

Use take-back schemes for the disposal of any unused veterinary medicinal product or waste materials derived thereof in accordance with local requirements and with any applicable national collection systems. These measures should help to protect the environment.

Ask your veterinary surgeon or pharmacist how to dispose of medicines no longer required.

13. Classification of veterinary medicinal products

Veterinary medicinal product subject to prescription.

14. Marketing authorisation numbers and pack sizes

Vm 06376/5061

Vm 06376/3061

Glass (Type I) vials of 250, 500, 1.000, 2.500, 5.000, 10.000 or 25.000 doses closed with a halogenobutyl rubber stopper and sealed with an aluminium cap.

Pack sizes:

Cardboard box containing 1, 2, 5, 10, 20 or 50 vials.

Not all pack sizes may be marketed.

15. PID link (Do not print heading)

[The following statement must be included where reference to the European Union Product Database is included on the product information. This statement is relevant to both UK(GB) and UK(NI) products:]

Find more product information by searching for the 'Product Information Database' on www.gov.uk.

16. Contact details

Marketing authorisation holder:

Intervet International B.V.
Wim de Körverstraat 35
5831 AN Boxmeer
Netherlands

Manufacturer responsible for the batch release:

Intervet International B.V.
Wim de Körverstraat 35
5831 AN Boxmeer
The Netherlands

Contact details to report suspected adverse reactions:

MSD Animal Health UK Limited
Tel.: +44 (0)1908 685685

Local representative:

MSD Animal Health UK Limited
Walton Manor
Walton
Milton Keynes
MK7 7AJ
United Kingdom

For any information about this veterinary medicinal product, please contact the local representative of the marketing authorisation holder listed below.

17. Other information

POM-V Veterinary medicinal product subject to prescription

Gavin Hall
Approved: 10 October 2025